Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder

Bibliography

• Buitelaar JK, Montgomery SA, Van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003;13:297-304
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Association; 2000. p. 85-102
   Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord 2005;9:384-91
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Miyahara S, Spencer T, et al, for the STEP-DB Investigators. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005;57:1467-73
   PubMed Web of Science ®Google Scholar
• Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1385-90
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52
   PubMed Web of Science ®Google Scholar
• Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004;18:1011-30
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44
   PubMed Web of Science ®Google Scholar
• Stein MA, Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contemp Pediatr 2003;20:83-110
   Google Scholar
• Faraone SV, Upadhyaya HP. Effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry 2007;68:e28
   PubMedGoogle Scholar
• Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006;83(Suppl 1):S8-14
   PubMedGoogle Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-18
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
   PubMed Web of Science ®Google Scholar
• McGough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 2003;42:684-91
   PubMed Web of Science ®Google Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6
   PubMed Web of Science ®Google Scholar
• Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11
   PubMed Web of Science ®Google Scholar
• Vyvanse (package insert). Wayne, PA: Shire US Inc; 2007
   Google Scholar
• Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-63
   PubMed Web of Science ®Google Scholar
• Jasinski D, Krishnan S. Abuse liability of intravenous lisdexamfetamine dimesylate (LDX; NRP104). Poster presented at the US Psychiatric and Mental Health 19th Annual Congress; 2006 November 15 – 19; New Orleans, LA
   Google Scholar
• Jasinski D, Krishnan S. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers. US Psychiatric and Mental Health 19th Annual Congress; 2006 November 15 – 19; New Orleans, LA
   Google Scholar
• Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19 – 24; San Diego, CA
   Google Scholar
• Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs 2007;9:129–35
   PubMedGoogle Scholar
• Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48:293-302
   PubMed Web of Science ®Google Scholar
• Arora M, Krishnan S. Bioavailability of lisdexamfetamine dimesylate in healthy volunteers when administered with or without food. American Psychiatric Association 58th Institute on Psychiatric Services; 2006 October 5 – 8; New York, NY
   Google Scholar
• Adderall XR [package insert]. Wayne, PA: Shire US Inc; 2007
   Google Scholar
• Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/hyperactivity disorder. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19 – 24; San Diego, CA
   Google Scholar
• Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006;8:4
   PubMedGoogle Scholar
• Biederman J, Boellner SW, Childress A, et al. Improvements in symptoms of attention-deficit/hyperactivity disorder in school-aged children with lisdexamfetamine (NRP104) and mixed amphetamine salts, extended-release versus placebo. 159th Annual Meeting of the American Psychiatric Association; 2006 May 25 – 28; Toronto, Ontario, Canada
   Google Scholar
• Adler L, Goodman DW, Kollins SH, et al. Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry; 2007 October 23 – 28; Boston, MA
   Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol in press
   Google Scholar
• McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006;9:476-85
   PubMedGoogle Scholar
• Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007;46:1138-47
   PubMed Web of Science ®Google Scholar